Sooriyaarachchi, M.Wedding, J.Harris, H.Gailer, J.2014-05-202014-05-202014Journal of Biological Inorganic Chemistry, 2014; 19(6):1049-10530949-82571432-1327http://hdl.handle.net/2440/83061Single drug-based cancer therapies are frequently associated with the development of drug resistance. To overcome this problem, combination therapy with two or more anticancer drugs is a promising strategy, but clinical studies are logistically challenging and costly. Intermediary in vitro studies, however, can provide critical insight to decide whether one should proceed to in vivo studies. To this end, cisplatin and the Ru-based anticancer drug NAMI-A were added to human plasma and the size distribution of Pt-containing and Ru-containing entities was determined over a 2 h period. The results revealed a dramatically different rate of plasma protein binding for each drug and/or their hydrolysis products. Both drugs bound to the same apparent plasma proteins, but crucially they did not adversely affect each other’s metabolism. Therefore, combination therapy of patients with these metallodrugs should be further assessed in clinical studies in order to systematically develop an effective combination therapy protocol to prevent the resurgence of cancer.en© SBIC 2014CisplatinNAMI-ACombination therapyPlasmaSize-exclusion chromatographyJournal article00300000462014051614362110.1007/s00775-014-1102-00003399751000282-s2.0-8490582067564052Harris, H. [0000-0002-3472-8628]